Given that Lumacaftor can inhibit DUSP18 activity and enhance the antitumor function of CD8+ T cells in vitro, the antitumor effect of Lumacaftor were subsequently assessed on tumor models in vivo. The gene discussed is CD8A; the disease is neoplasm.